|Day Low/High||13.18 / 14.00|
|52 Wk Low/High||13.14 / 27.43|
Seven investment experts participating in Moneyshow's Top Picks 2022 report share their ideas for healthy portfolio gains in 2022.
Chasing this move may seem undisciplined, but here's what helps to reduce risk.
The beaten-down biotech sector had one of the best weeks in a year. Are these names still oversold?
Many of the stocks favored by speculative traders are coming on strong.
Of 56 recent ARKK buys, only two are trading in positive territory Wednesday.
Trading in biotech stocks and a particular SPAC play are on my mind.
Quite a few stocks are fading right now -- not due to poor fundamentals, but due to lack of buying interest.
Next week we are likely to see some shift in the focus of the market as we move back to macro and big picture issues.
Now's the time to take a step back and prepare mentally for what happens next.
It makes logical sense to take your foot off the gas here.
It is logical that stocks consolidate a little as we head into earnings season.
As the pundits decide who won, I'm looking at these biotech names with a focus on Myovant Sciences.
Shares of Heron Therapeutics and Myovant Sciences have taken hits but both companies still show promise.
You need to be selective and manage positions carefully.
As this healthy bounce boosts the market, I'm seeing opportunities in these special purpose acquisition companies.
Here are several names I'm looking to build on further weakness.
Small-caps are also benefitting from the move, but momentum-chasing has slowed.
Biotechnology is always high risk but the right plays move unlike anything else.
It continues to be a market for speculative trading.
I'm doing some dip buying amid weakness in large-cap tech stocks.
The good news right now is that selling is not highly correlated.
The market trend is up and that's all that matters in the short term.
It continues to be a very good market for aggressive traders that focus on stock-picking and sectors.
A weak close will be a key sign that a change in character might be coming.